Alberta Investment Management Corp Buys Shares of 823,120 agilon health, inc. (NYSE:AGL)

Alberta Investment Management Corp bought a new position in agilon health, inc. (NYSE:AGL) during the 4th quarter, according to its most recent disclosure with the Securities and Exchange Commission. The institutional investor bought 823,120 shares of the company’s stock, valued at approximately $1,564,000.

A number of other hedge funds and other institutional investors also recently made changes to their positions in the company. Rhumbline Advisers grew its stake in shares of agilon health by 6.2% in the 4th quarter. Rhumbline Advisers now owns 419,587 shares of the company’s stock valued at $797,000 after buying an additional 24,420 shares in the last quarter. Empowered Funds LLC acquired a new stake in agilon health in the fourth quarter valued at approximately $97,000. First Citizens Bank & Trust Co. bought a new stake in agilon health in the fourth quarter worth approximately $46,000. Inspire Investing LLC increased its stake in shares of agilon health by 106.6% during the 4th quarter. Inspire Investing LLC now owns 217,550 shares of the company’s stock worth $413,000 after purchasing an additional 112,241 shares during the last quarter. Finally, Oak Thistle LLC bought a new position in shares of agilon health during the 4th quarter valued at $25,000.

agilon health Stock Performance

NYSE AGL opened at $3.53 on Friday. The company has a debt-to-equity ratio of 0.06, a current ratio of 1.29 and a quick ratio of 1.29. The company’s fifty day moving average is $2.82 and its two-hundred day moving average is $3.11. agilon health, inc. has a 52-week low of $1.50 and a 52-week high of $7.73. The firm has a market capitalization of $1.45 billion, a price-to-earnings ratio of -3.75 and a beta of 0.67.

Insider Activity at agilon health

In other agilon health news, Director Diana Mckenzie bought 12,500 shares of the firm’s stock in a transaction dated Monday, November 25th. The shares were acquired at an average cost of $2.28 per share, for a total transaction of $28,500.00. Following the transaction, the director now owns 51,319 shares in the company, valued at approximately $117,007.32. The trade was a 32.20 % increase in their ownership of the stock. The acquisition was disclosed in a legal filing with the SEC, which is available through the SEC website. Also, Director John William Wulf purchased 45,000 shares of the company’s stock in a transaction that occurred on Thursday, December 5th. The stock was acquired at an average cost of $2.18 per share, with a total value of $98,100.00. Following the transaction, the director now directly owns 206,133 shares of the company’s stock, valued at approximately $449,369.94. This represents a 27.93 % increase in their ownership of the stock. The disclosure for this purchase can be found here. Insiders have bought 90,000 shares of company stock worth $198,100 over the last three months. Company insiders own 3.20% of the company’s stock.

Analysts Set New Price Targets

AGL has been the subject of a number of recent research reports. TD Cowen decreased their price objective on shares of agilon health from $6.00 to $2.00 and set a “hold” rating for the company in a report on Monday, November 11th. Royal Bank of Canada reiterated an “outperform” rating and set a $3.00 price target on shares of agilon health in a research note on Tuesday, November 19th. Barclays cut their price objective on agilon health from $5.00 to $2.00 and set an “underweight” rating on the stock in a research note on Monday, November 11th. William Blair lowered agilon health from an “outperform” rating to a “market perform” rating in a report on Friday, November 8th. Finally, Macquarie started coverage on agilon health in a report on Monday, December 16th. They set a “neutral” rating and a $3.00 price target on the stock. Two equities research analysts have rated the stock with a sell rating, fourteen have assigned a hold rating and two have assigned a buy rating to the company. According to MarketBeat.com, agilon health currently has a consensus rating of “Hold” and an average target price of $4.03.

agilon health Company Profile

agilon health, inc. provides healthcare services for seniors through primary care physicians in the communities of the United States. It offers a platform that manages the total healthcare needs of the patients by subscription-like per-member per-month. The company was formerly known as Agilon Health Topco, Inc and changed its name to agilon health, inc.